Alpha Cognition Inc. Toronto S.E.

Equities

ACOG

CA02074J2048

Biotechnology & Medical Research

End-of-day quote Toronto S.E. Other stock markets			5-day change	1st Jan Change
- ^CAD	-.--%		-.--%	-.--%

Apr. 04	Alpha Cognition's Q4 Comprehensive Loss Widens A Bit From Year Earlier Period	MT
Apr. 04	Alpha Cognition Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Alpha Cognition Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 25, 2022 at 06:57 pm EDT

Alpha Cognition Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 3 million compared to net income of USD 0.118673 million a year ago. Basic loss per share from continuing operations was USD 0.05.
For the six months, net loss was USD 5.92 million compared to USD 12.11 million a year ago. Basic loss per share from continuing operations was USD 0.09 compared to USD 0.25 a year ago.

Latest news about Alpha Cognition Inc.

Alpha Cognition's Q4 Comprehensive Loss Widens A Bit From Year Earlier Period	Apr. 04	MT
Alpha Cognition Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 03	CI
Alpha Cognition Inc. Files Composition-Of-M Matter Patent	Feb. 22	CI
Alpha Cognition Inc. announced that it has received $8.45 million in funding	Jan. 18	CI
Alpha Cognition Inc. Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-To-Moderate Alzheimer's Disease	Dec. 07	CI
Alpha Cognition Reports Amended Terms of Private Placement, Continuation of the Offering	Dec. 05	MT
Alpha Cognition Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28	CI
Alpha Cognition Inc. Announces Submission of New Drug Application to the FDA for ALPHA-1062 for Mild-to-Moderate Alzheimer?s Disease	23-09-27	CI
Alpha Cognition Inc. announced that it has received $1.345093 million in funding	23-08-30	CI
Alpha Cognition Inc. announces tranche update	23-08-30	CI
Alpha Cognition Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-22	CI
Alpha Cognition Inc. Receives Notice of Allowance for U.S. Patent Application Covering Use of ALPHA-1062 for Mild to Moderate Alzheimer's Disease	23-08-14	CI
Alpha Cognition Inc. Receives $750,000 Grant from the Army Medical Research and Material Command	23-06-08	CI
Alpha Cognition Narrows Q1 Loss	23-05-30	MT
Alpha Cognition Announces Provides Update on New Drug Application for ALPHA-1062	23-05-30	CI
Alpha Cognition Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-30	CI
Alpha Cognition Plans Private Placement	23-05-30	MT
Alpha Cognition Inc. announced that it expects to receive $6.500001 million in funding	23-05-29	CI
Alpha Cognition Inc. announced that it expects to receive $6.5 million in funding	23-05-29	CI

Chart Alpha Cognition Inc.

Duration

Period

More charts

Company Profile

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Companyâs pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Companyâs ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimerâs dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.

Sector

Biotechnology & Medical Research

Calendar

2024-05-27 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.65 CAD

Average target price

1 CAD

Spread / Average Target

+53.85%

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research